Overview
FLGT market data
Price History
FLGT price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$1.97 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.97 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -26.1% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $13.46 – $31.04 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $513.3M · P/B 0.73 · P/S 1.58.
Company News
Piper Sandler Maintains Neutral on Fulgent Genetics, Raises Price Target to $19Benzinga · Aug 4, 2026, 2:35 PM
Fulgent Genetics shares are trading lower after the company reported worse-than-expected Q2 financial results and lowered its FY2026 adjusted EPS and FY2026 sales guidance.Benzinga · Jul 31, 2026, 1:20 PM
Apple, Stryker, Coinbase And Other Big Stocks Moving Lower In Friday’s Pre-Market SessionBenzinga · Jul 31, 2026, 12:02 PM
Fulgent Genetics Lowers FY2026 Adj EPS Guidance from $(1.59) to $(2.35)-$(2.22) vs $(1.55) Est; Lowers FY2026 Sales Guidance from $350.000M to $330.000M-$340.000M vs $351.900M EstBenzinga · Jul 30, 2026, 8:19 PM
8-K filing — Fulgent Genetics, Inc. (FLGT)SEC EDGAR · Jul 30, 2026, 8:09 PM
Fulgent Genetics Q2 Adj. EPS $(0.58) Misses $(0.46) Estimate, Sales $85.389M Miss $94.000M EstimateBenzinga · Jul 30, 2026, 8:06 PM
Reported Earlier, Fulgent Genetic Announced It Presented Updated Data In The Head And Neck Cancer Track During The American Society Of Clinical Oncology 2026 Annual Meeting Rapid Oral Abstract Session In Hall D1 At Mccormick Place In ChicagoBenzinga · Jun 2, 2026, 8:14 AM
Fulgent Genetics' FID-007 Plus Cetuximab Shows 60% Response Rate And 7.2-Month Median PFS In Phase 2 Head And Neck Cancer Study With Favorable Safety ProfileBenzinga · May 21, 2026, 9:15 PM